RGC (Regencell Bioscience Holdings) EV-to-EBIT : -580.72 (As of May. 12, 2025)

Regencell Bioscience Holdings EV-to-EBIT Chart

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-EBIT	Get a 7-Day Free Trial						-57.06	-	-46.01	-	-7.57

Competitive Comparison of Regencell Bioscience Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's EV-to-EBIT falls into.

Regencell Bioscience Holdings EV-to-EBIT Calculation

Regencell Bioscience Holdings's EV-to-EBIT for today is calculated as:

Regencell Bioscience Holdings's current Enterprise Value is $2,750.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-4.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings  (NAS:RGC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Regencell Bioscience Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Regencell Bioscience Holdings's Enterprise Value for the quarter that ended in Jun. 2024 was $35.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-4.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings Business Description